血栓形成は,薬剤排出ステントのための動脈薬配分を調節する
Chao-Wei Hwang1, Andrew D Levin, Michael Jonas
1Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge 02139, USA. cwhwang@post.harvard.edu
Circulation
|March 30, 2005
まとめ
薬剤排出ステントの血栓は,薬物の投与に大きく影響し,予測不可能な動脈吸収を引き起こします. 凝固を制御または除去することは,一貫した薬物の堆積のために非常に重要です.
科学分野:
- バイオメディカルエンジニアリング
- 心血管研究 循環器科の研究
- 薬物の配送システムです.
背景:
- 薬剤排出ステント (DES) は,強力な薬物を動脈に投与するために使用されます.
- ステントは,展開時に血栓 (血栓) で負荷される可能性があります.
- 薬物のエリューションと動脈の吸収に対する血栓の効果は完全に理解されていません.
研究 の 目的:
- 血栓の組成と幾何学が,DESからのパクリタキセル輸送にどのように影響するか調査する.
- 薬物のエリューションと動脈の吸収に対する血栓の影響を決定する.
- 計算モデルをin vivoデータで検証する.
主な方法:
- パクリタキセルの輸送と保持を様々な凝固組成物 (フィブリン,フィブリン-赤血球,全血) で評価した.
- 凝固とステントの幾何学に基づいて薬物の輸送を予測するために計算モデリングを使用しました.
- 誘発性血栓形成によるステント付き大動脈の新しいラットモデルを使用して,モデルの予測を検証した.
主要な成果:
- パクリタキセルの拡散性は,凝固組織によって著しく変化し,フィブリンでは最も速く,全血凝固では最も遅かった.
- 血液細胞はパクリタキセルと結合し,特に生理学的血圧値で,凝固内の保持率が高くなります.
- 計算モデルとネズミの研究は,血栓の幾何学が薬物の摂取を左右し,減少 (動脈とステントの間の血栓) または増加 (ステントの上部にある血栓) することを示しました.
結論:
- ステントの血栓は,薬物の吸収と堆積の実質的な変動を引き起こします.
- 凝固とステントの間の幾何学的な関係は,薬物の投与結果に大きな影響を与えます.
- 血栓の効果的な制御または除去は,DESからの予測可能な薬物投与のために不可欠です.
関連する概念動画
Drug Distribution: Tissue Binding
3.7K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
3.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Venous Thrombosis I: Introduction
834
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
834
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482


